Antibody fusions with immunomodulatory proteins for cancer therapy.
作者： Dafne Müller
DOI: 10.1016/J.PHARMTHERA.2015.07.001
关键词:
摘要: The potential of immunomodulatory proteins, in particular cytokines, for cancer therapy is well recognized, but hampered by the toxicity associated with their systemic application. In order to address this problem, targeted delivery antibody fusion proteins has been early proposed and development intensively pursued over last decade. Here, factors influencing selection modification cytokines formats approach are being discussed, indicating current developments translational advances field.
elsevier.com
sci-hub.se 参考文章(124)
Leisha A. Emens, Richa Gupta, GM-CSF-secreting vaccines for solid tumors: moving forward. Discovery Medicine. ,vol. 10, pp. 52- 60 ,(2010)
Nicole Müller, Agnes Wyzgol, Sabine Münkel, Klaus Pfizenmaier, Harald Wajant, Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS Journal. ,vol. 275, pp. 2296- 2304 ,(2008) , 10.1111/J.1742-4658.2008.06382.X
Marie Vincent, Anne Bessard, Denis Cochonneau, Géraldine Teppaz, Véronique Solé, Mike Maillasson, Stéphane Birklé, Laure Garrigue-Antar, Agnès Quéméner, Yannick Jacques, Tumor targeting of the IL‐15 superagonist RLI by an anti‐GD2 antibody strongly enhances its antitumor potency International Journal of Cancer. ,vol. 133, pp. 757- 765 ,(2013) , 10.1002/IJC.28059
Paul Carter, Improving the efficacy of antibody-based cancer therapies Nature Reviews Cancer. ,vol. 1, pp. 118- 129 ,(2001) , 10.1038/35101072
Stephen D. Gillies, John Wesolowski, Kin-Ming Lo, Michael Super, Yan Lan, Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Research. ,vol. 59, pp. 2159- 2166 ,(1999)
Valeria Nicolini, Inja Waldhauer, Anne Freimoser, Sara Colombetti, Federica Cavallo, Marina Bacac, Christian Gerdes, Pablo Umana, Christian Klein, Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo Cancer Research. ,vol. 74, pp. 2579- 2579 ,(2014) , 10.1158/1538-7445.AM2014-2579
Thomas Waldmann, The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Research & Therapy. ,vol. 4, pp. 1- 7 ,(2002) , 10.1186/AR584
Sigrid Dubois, Hiral J. Patel, Meili Zhang, Thomas A. Waldmann, Jürgen R. Müller, Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action Journal of Immunology. ,vol. 180, pp. 2099- 2106 ,(2008) , 10.4049/JIMMUNOL.180.4.2099
Paul M. Sondel, Jacquelyn A. Hank, Peter Jaeger, Stephen D. Gillies, Jacek Gan, Jean E. Surfus, Ralph A. Reisfeld, Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clinical Cancer Research. ,vol. 2, pp. 1951- 1959 ,(1996)
Hartwig Kosmehl, Luciano Zardi, Verena Gafner, Laura Borsi, Cornelia Halin, Dario Neri, Alexander Berndt, Maria Elena Villani, Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor α Cancer Research. ,vol. 63, pp. 3202- 3210 ,(2003)